NCCS joined with a group of patient and provider advocacy groups in a letter to the National Academy of Medicine (NAM) on vaccine allocation. In the letter, the groups articulate the substantial risk that cancer patients face during the pandemic and shared data on the negative outcomes of patients with ...

The National Coalition for Cancer Survivorship (NCCS) submitted comments in response to an Informal Request for Information on the proposed Oncology Care First Model. This model was released by the Centers for Medicare and Medicaid Services (CMS). The comments focus on concerns regarding adequate resources in the model to support ...

The National Coalition for Cancer Survivorship (NCCS) joined with AARP and 47 other organizations in letters to the House and Senate asking Members to co-sponsor the Medical Expense Savings Act, which is bipartisan legislation that would make permanent the 7.5 percent threshold for the medical expense deduction. This deduction provides ...

NCCS joined with public health and medical organizations in a comment letter to the U.S. Food and Drug Administration (FDA) regarding the proposed rule to establish health warnings for cigarette packages and advertisements. The comment letter outlines the overwhelming evidence that shows color graphic health warnings on cigarette packages and ...

The Department of Health and Human Services (HHS) released recently a proposed rule to change Medicare Part D’s protected classes drug coverage. In response, NCCS joined with other patient and provider groups of the Cancer Leadership Council (CLC) to comment on how these proposed changes could impact patients. The proposed ...

On December 31st, NCCS submitted our final comment letter of the year to the Centers for Medicare and Medicaid Services regarding the advance notice of proposed rulemaking for the Medicare Part B drug program. In the letter, we outlined concerns that this proposal could have on Medicare beneficiaries such as ...

Earlier this year, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would require information about drug costs be included in direct-to-consumer (DTC) advertisements of prescription drugs and biological products. NCCS issued a statement regarding the proposal, saying, “While we understand [...] ...

NCCS joined with other cancer organizations of the Cancer Leadership Council (CLC) in a letter to the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) regarding the new plan announced on August 7 that gives Medicare Advantage plans the option of applying ...

NCCS submitted a letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed update to the hospital outpatient prospective payment system, known as OPPS, for calendar year 2019. In the letter, NCCS outlines support for a change in payment for clinical services that are provided at off-campus ...

NCCS joined with other organizations of the Cancer Leadership Council (CLC) in commenting on the FDA Biosimilar Action Plan (BAP). The comment letter commended the FDA for the development of a plan that balances both innovation and competition. The letter stated that these products provide significant benefits to cancer patients, ...